Literature DB >> 25772432

Chemical structure-related mechanisms underlying in vivo genotoxicity induced by nitrofurantoin and its constituent moieties in gpt delta rats.

Aki Kijima1, Yuji Ishii1, Shinji Takasu1, Kohei Matsushita1, Ken Kuroda1, Daisuke Hibi1, Yuta Suzuki1, Takehiko Nohmi2, Takashi Umemura3.   

Abstract

Nitrofurans are antimicrobial compounds containing a nitro group at the 5-position of the furan ring and an amine or hydrazide side chain derivative. One member of the nitrofurans, nitrofurantoin (NFT), is a renal carcinogen in male rats despite its still controversial genotoxicity. We investigated chemical structure-related modes of action of NFT, and reporter gene mutation assays for NFT and its constituent moieties were performed. NFT, 5-nitro-2-furaldehyde (NFA), or 1-aminohydantoin (AHD) was administered to male F344 gpt delta rats by gavage for 4 or 13 weeks at a carcinogenic or the maximum tolerated dose. NFT caused a significant increase in gpt mutant frequency (MF) at 13 weeks with G-base substitution mutations. An increase in gpt MF was also observed in the NFA-treated group at 13 weeks, but not in the AHD-treated group. 8-Hydroxydeoxyguanosine (8-OHdG) levels in the kidney DNA of NFT-treated rats were significantly increased after 4 weeks. NFT caused accumulation of hyaline droplets indicated by positive immunostaining and western blot analysis for α2u-globulin in the proximal tubules. An additional study, in which female gpt delta rats were given NFT at the same dose used for males, was performed to mitigate the effect of α2u-globulin. NFT exerted the same effects on female rat kidneys to the same extent as males in terms of gpt MF and 8-OHdG level. Thus, it is highly probable that the structure of the nitro furan plays a key role in NFT-induced genotoxicity and genotoxic mechanisms including oxidative DNA damage are involved in NFT-induced renal carcinogenesis. α2u-globulin-mediated nephropathy may be a prerequisite for NFT-induced renal carcinogenesis in male rats, and additionally NFT could be a latent carcinogen in female rats and other animal species.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  In vivo mutagenicity; Kidney; Nitrofurantoin; gpt delta rat

Mesh:

Substances:

Year:  2015        PMID: 25772432     DOI: 10.1016/j.tox.2015.03.003

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  5 in total

1.  Simultaneous electrochemical determination of nitrofurantoin and nifedipine with assistance of needle-shaped perovskite structure: barium stannate fabricated glassy carbon electrode.

Authors:  Muthukutty Balamurugan; Krishnapandi Alagumalai; Tse-Wei Chen; Shen-Ming Chen; Xiaoheng Liu; Muthusamy Selvaganapathy
Journal:  Mikrochim Acta       Date:  2021-01-06       Impact factor: 5.833

2.  Role of oxidative stress in the chemical structure-related genotoxicity of nitrofurantoin in Nrf2-deficient gpt delta mice.

Authors:  Takuma Tsuchiya; Aki Kijima; Yuji Ishii; Shinji Takasu; Yuh Yokoo; Akiyoshi Nishikawa; Tokuma Yanai; Takashi Umemura
Journal:  J Toxicol Pathol       Date:  2018-06-02       Impact factor: 1.628

3.  Mechanisms of oxidative stress-induced in vivo mutagenicity by potassium bromate and nitrofurantoin.

Authors:  Takuma Tsuchiya; Aki Kijima; Yuji Ishii; Shinji Takasu; Yuh Yokoo; Akiyoshi Nishikawa; Tokuma Yanai; Takashi Umemura
Journal:  J Toxicol Pathol       Date:  2018-06-02       Impact factor: 1.628

4.  Nitrofurantoin-Microbial Degradation and Interactions with Environmental Bacterial Strains.

Authors:  Amanda Pacholak; Wojciech Smułek; Agnieszka Zgoła-Grześkowiak; Ewa Kaczorek
Journal:  Int J Environ Res Public Health       Date:  2019-04-30       Impact factor: 3.390

5.  Risk of Cancer after Lower Urinary Tract Infection: A Population-Based Cohort Study.

Authors:  Chia-Hung Huang; Ying-Hsiang Chou; Han-Wei Yeh; Jing-Yang Huang; Shun-Fa Yang; Chao-Bin Yeh
Journal:  Int J Environ Res Public Health       Date:  2019-01-30       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.